Fulgent Genetics Forecasts $1.59 Adjusted Loss Per Share for 2026
summarizeSummary
Fulgent Genetics has provided specific guidance, projecting an adjusted loss per share of $1.59 for the full year 2026. This announcement quantifies the negative financial outlook previously indicated in the company's 10-K filing from February, which highlighted increased net losses and an anticipated significant revenue decline for 2026 due to a major customer insourcing services. The specific loss per share figure provides a concrete financial target for the expected underperformance, reinforcing the challenging operational environment. Given the stock is already trading near its 52-week low, this specific negative guidance is material and could further pressure shares. Traders will be watching for any signs of stabilization or new revenue streams that could mitigate these projected losses.
At the time of this announcement, FLGT was trading at $13.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $451.9M. The 52-week trading range was $13.46 to $31.04. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.